Deformed epidermal autoregulatory factor-1 (DEAF1), a transcription factor essential for central nervous system and early embryonic development, has recently been implicated in a series of intellectual disability-related neurodevelopmental anomalies termed, in this study, as DEAF1-associated neurodevelopmental disorder (DAND). We identified six potentially deleterious DEAF1 
INTRODUCTION
Intellectual disability (ID) is a common neurodevelopmental disorder with high clinical and genetic heterogeneity that has a world-wide prevalence of ∼1% (Maulik, Mascarenhas, Mathers, Dua, & Saxena, 2011) . ID is characterized by various degrees of cognitive dysfunction and maladaptive behaviors (American Psychiatric Association 2013) and can occur either in isolation (nonsyndromic) or in conjunction with other clinical and physical features. Trio-and proband-based clinical exome sequencing (CES) has greatly increased the number of candidate genetic loci contributing to ID (Rump et al., 2016) , and the functional significance of these genetic variants is under active investigation. Recent CES studies have identified a potential role for deformed epidermal autoregulatory factor-1 (DEAF1; MIM# 602635; NM_021008.3) in both autosomal dominant and autosomal recessive modes of inheritance in a neurodevelopmental disorder comprising ID, speech impairment, motor developmental delay, (MRD24; MIM# 615828; MIM# 617171) (Rauch et al., 2012; Vissers et al., 2010; Vulto-van Silfhout et al., 2014) , and additional phenotypes such as seizures, brain malformations, and autism (Faqeih et al., 2014; Gund, Powis, Alcaraz, Desai, & Baranano, 2016; Rajab et al., 2015; Waltl, 2014; Wenger, Guturu, Bernstein, & Bejerano, 2017) , as well as a Smith-Magenis syndrome (SMS; MIM# 182290)-like phenotype that includes ID, dysmorphic features, and sleep disturbances (Berger et al., 2017) . In this study, we use DEAF1-associated neurodevelopmental disorder (DAND) to describe a series of ID-related neurodevelopmental anomalies that are associated with pathogenic DEAF1 variants and share a common set of clinical features.
DEAF1 encodes an autoregulatory transcription factor that activates or represses the expression of various target genes (Czesak et al., 2012; Czesak, Lemonde, Peterson, Rogaeva, & Albert, 2006; Jensik et al., 2014) . The protein is composed of multiple structural domains including a SAND domain (Sp-100, AIRE, NucP41/75, and DEAF1), which is required for DNA binding (via a KDWK motif that binds consensus TTCG sequences in gene regulatory regions (Huggenvik et al., 1998) ); a monopartite nuclear localization signal (NLS) and a leucinerich nuclear export signal (NES), and a cysteine-rich MYND domain (myeloid translocation protein 8, Nervy, and DEAF1) in the C-terminus that mediates protein-protein interactions (Vulto-van Silfhout et al., 2014) . DEAF1 is essential for early embryonic and neuronal development. Disruption of Deaf1 function results in embryonic arrest and severe defects in early embryonic patterning in drosophila (Veraksa, Kennison, & McGinnis, 2002) , and neural tube defects (Hahm et al., 2004) , as well as impaired contextual memory and increased anxietyrelated behavior in mice (Vulto-van Silfhout et al., 2014) . DEAF1 is highly expressed in brain (Gross & McGinnis, 1996; Vulto-van Silfhout et al., 2014; Waltl 2014) and has been associated with neuropsychiatric disorders such as major depression and suicide (Czesak et al., 2012; Czesak et al., 2006; Lemonde et al., 2003) .
Previous studies identified six de novo heterozygous missense variants within the DEAF1 SAND domain. Variants c.670C > T p.Arg224Trp, c.762A > C p.Arg254Ser (Vulto-van Silfhout et al., 2014) , and c.683T > G p.Ile228Ser (Vissers et al., 2010; Vulto-van Silfhout et al., 2014) were reported in three unrelated MRD24 (MIM# 615828) patients, and c.791A > C p.Gln264Pro (Rauch et al., 2012; Vultovan Silfhout et al., 2014) in a nonsyndromic ID patient. Each variant produced an altered DEAF1 protein with absent or significantly reduced DNA binding and the inability to repress its own promoter.
Two additional de novo variants, c.700T > A p.Trp234Arg (Berger et al., 2017) and c.737G > C p.Arg246Thr (Wenger et al., 2017) , were recently identified in a SMS-like patient and an ID patient with autism and sleep difficulties, respectively. An inherited homozygous SAND variant c.676C > T p.Arg226Trp was found in two related individuals from a consanguineous Saudi Arabian family displaying ID, microcephaly, hypotonia, white matter abnormalities and seizure (Faqeih et al., 2014) , and in a third individual from an unrelated consanguineous Saudi Arabian family with similar features but no evidence of white matter disease (Gund et al., 2016) . Functional properties of this variant, however, have not yet been reported. Another inherited homozygous c.997+4A > C p.(Gly292Profs*) splice acceptor change was found in three related individuals from a consanguineous Omani family with ID, autism, hypotonia, motor and speech delay, dyskinesia of the limbs, seizures, and abnormal brain MRI. Functional analysis of this variant revealed exon skipping and a 95% reduction in DEAF1 mRNA (Rajab et al., 2015) .
In this study, we identified six DEAF1 variants within the SAND and NLS domains through CES of pediatric patients with developmental delay and other clinical features of unknown etiology. To ascertain whether these candidate variants are potentially pathogenic, we carried out molecular experiments to assess the effects of the amino acid substitutions or small deletions on human DEAF1 function. Our results demonstrate that these variants severely affect DEAF1 transcriptional activities, DNA binding, and intracellular localization and thereby further support a role for DEAF1 as an underlying cause of clinical phenotypes in these individuals. These findings illustrate the importance of functional characterization of CES variants of uncertain significance (VUS) for revealing gene variant properties and improving diagnosis.
MATERIALS AND METHODS

CES and patient information
Individuals with pediatric onset neurological abnormalities were referred for CES at Baylor Genetics (Houston, TX). Clinical data and peripheral blood samples from the patients and their parents were provided by the referring physician. Exome sequencing and variant calling were performed as previously described (Yang et al., 2013; Yang et al., 2014) . After data analysis, candidate DEAF1 variants were confirmed by Sanger Sequencing, at which point the parental samples were also analyzed (described in details in section Identification of Candidate DEAF1 Variants). One DEAF1 variant c.737G > C p.Arg246Thr in one of the individuals (561, 320) was recently reported in an exome reanalysis cohort as a likely pathogenic variant, but without accompanying functional studies (Wenger et al., 2017) .
Exome and clinical data for another individual (M2647) carrying a de novo DEAF1 variant c.700T > A p.Trp234Arg were provided for inclusion in this report by two co-authors (S.B. and A.C.M.S.) (Berger et al., 2017 (Willemsen et al., 2012) , and Charot-Marie-Tooth disease type 2O (CMT2O; MIM# 614228) (Weedon et al., 2011) .
Although the clinical phenotypes of Subject 6 were not fully represented by these disorders (e.g., ASD phenotype with family history was not reported in patients carrying DYNC1H1 variants), and most pathogenic DYNC1H1 variants reported are localized in tail domain (53-1,867 aa) and stalk domain (3,189-3,500) of this gene (ClinVar database, https://www.ncbi.nlm.nih.gov/clinvar) (Harms et al., 2012) , further study is still required to elucidate whether DYNC1H1 plays a role in the patient's phenotype.
Plasmid construction
Construction of pcDNA3-based expression plasmids encoding carboxyl-terminal FLAG or HA epitope-tagged human DEAF1 cDNA (RefSeq NM_021008.3) has previously been described (Jensik, Huggenvik, & Collard, 2004) . The DNA mutation numbering system used in this study is based on cDNA sequence. Nucleotide numbering designates the A of the ATG translation initiation codon in the reference sequence as +1 and the initiation codon as codon 1. . Table S2 ). Digested PCR fragments were used to replace the corresponding regions of wild-type (WT) DEAF1. All inserts were confirmed by standard Sanger sequencing.
Electrophoretic mobility shift assay
Epitope FLAG-tagged WT or variant DEAF1 recombinant proteins were purified from transfected human embryonic kidney (HEK293T) cells, as previously described (Jensik, Huggenvik, & Collard, 2012) . Proteins used in serial dilution electrophoretic mobility shift assay (EMSA) were concentrated using Amicon Ultra 30K devices in storage buffer that included 0.1% deoxycholate and 1 mM DTT. EMSA analysis was performed using two verified probes: a IRDye800 labeled doublestranded (ds) DNA probe N52-69 (11 space probe) corresponding to the consensus human DEAF1 promoter binding sequence (Bottomley et al., 2001; Michelson et al., 1999) or a IRDye700 labeled probe S6con (6 space probe) corresponding to a high-affinity preferred DEAF1 binding motif (Jensik et al., 2004; Jensik et al., 2014; Vulto-van Silfhout et al., 2014) . Recombinant DEAF1 proteins (850 fmol) were incubated with 500 fmol of dsDNA probe and 1 g of poly(dA-dT) (nonspecific competitor) in a 20 l reaction containing 70 mM KCl, 35 mM Tris, pH 7.5, 0.7 mM DTT, 2.0% (v/v) glycerol for 20 min at room temperature. Protein-DNA complexes were separated in 4.0% non-denaturing polyacrylamide gels and probe migration was visualized on a Licor Odyssey CLx.
Luciferase reporter assay
Transcription assays using the pDEAF1 promoter-firefly luciferase construct have been previously described (Vulto-van Silfhout et al., 2014) .
Briefly, HEK293T cells were plated in 1 ml DMEM in each well of 24-well plates (90,000 cells per well) and transfected in duplicate with 125 ng pcDNA3 (control) or DEAF1 (WT or DEAF1 variants) expression plasmids with 375 ng pDEAF1 promoter-firefly luciferase and 1.25 ng Renilla luciferase expression plasmid for normalization using the calcium phosphate technique. Luciferase assays were performed 24 hr later using the Dual-Luciferase Reporter Assay System Promega (Madison, Wisconsin, USA).
Immunofluorescence staining
HEK293T cells on 60 mm dishes were transfected with 1.0 g of Flag epitope-tagged WT or DEAF1 variants expression constructs, or cotransfected with 500 ng of WT DEAF1-HA and 500 ng of p.K305del-Flag, by calcium phosphate precipitation. Twenty-four hours later, cells were fixed in 4% paraformaldehyde, permeabilized in methanol, and incubated with rabbit anti-DEAF1(1:1,000) followed by Cy3-conjugated goat anti-rabbit IgG (1:1,000) (Huggenvik et al., 1998) , or rabbit anti-HA (1:1,000) and mouse anti-FLAG (1:1,000) followed by Cy3-conjugated goat anti-rabbit IgG and Alexafluor-488-conjugated donkey anti-mouse IgG (1:1,000) (Vulto-van Silfhout et al., 2014) . DNA was stained with Hoechst dye 33258 (1.0 g/ml). Cells were visualized with an Olympus BW50 fluorescence microscope with a 60× water objective. 
RESULTS
Identification of candidate DEAF1 variants
To identify novel DEAF1 deleterious variants, we searched the Baylor Genetics internal CES database comprising 6,067 individuals, and identified 248 individuals harboring a total of 83 distinct DEAF1 variants.
To screen for candidate pathogenic DEAF1 variants, we focused on rare variants with frequencies less than 0.1% in the 1000 Genomes Project (www.1000genomes.org), dbSNP (www.ncbi.nlm.nih.gov/snp/), ExAC (exac.broadinstitute.org), and National Heart, Lung, and Blood Institute GO Exome Sequencing Project (ESP5400, https://evs.gs.washin gton.edu/EVS) databases. Synonymous variants likely to be benign or VUS as assessed by PolyPhen 2 (Adzhubei et al., 2010) (https://genetics.bwh.harvard.edu/pph2/, HumVar or HumDiv scores < 0.95) and/or SIFT (Kumar, Henikoff, & Ng, 2009) Since both autosomal dominant and autosomal recessive modes of inheritance were reported for DEAF1-associated cases (Supp . Table   S4 ), we focused on both de novo and biallelically inherited variants in probands. The retained variants were validated by Sanger sequencing, and tested for co-segregation by analyzing parental DNA samples.
CES data obtained at NHGRI NIH (Berger et al., 2017) were analyzed using ANNOVAR (Wang, Li, & Hakonarson, 2010) (https://annovar.openbioinformatics.org/) (Supp . Table S3 ), focusing on rare variants with frequencies less than 0.1% in ExAC database and variants predicted to be deleterious based on a Combined Annotation Dependent Depletion (CADD) (Kircher, Witten, Jain, O'Roak, & Cooper, 2014) scores >20 for different Mendelian inheritance models in the trios.
Our final list of six candidate DEAF1 variants is shown in Figure 1A and 
In silico analysis of DEAF1 variants
Among the variants mentioned above, five are missense variants located within the SAND domain, an essential region for transcriptional activation or repression, and the other one, p.K305del, is a 3-bp in-frame deletion within the NLS domain ( Figure 1A ). With the exception of p.R226W, which was homozygous and inherited from each parent, all of the remaining variants were heterozygous in the probands and not detected in their parents. All variants affected evolutionarily conserved amino acids ( Figure 1B (Bottomley et al., 2001; Vulto-van Silfhout et al., 2014) , was used as a control. Each bar represents the mean ± SEM of the normalized luciferase activities from at least three independent experiments with the activity of the DEAF1 promoter co-transfected with the control plasmid pcDNA3 set to 1. Data were analyzed by one-way ANOVA followed by Dunnett's multiple comparison post hoc test. *P < 0.01 for expression in the presence of co-expressed DEAF1 variants versus WT DEAF1. Co-expression of the previously identified DEAF1 variant p.R226W did not show a significant difference in repression activity compared to WT DEAF1 p.Q264P (Vulto-van Silfhout et al., 2014) , the variants identified in this study are likely to change DEAF1 protein conformation based on changes in amino acid charge, steric effect, hydrophobic or ionic interactions, and thus potentially damage protein function. The predicted pathogenicity of the variants were classified according to American College of Medical Genetics and Genomics (ACMG) guidelines (Richards et al., 2015) (Table 1) .
Clinical features of individuals with DEAF1 variants
The key clinical features of six unrelated subjects harboring the potentially deleterious DEAF1 variants described above are summarized in Table 2 . All of the subjects, four female and two males with an age range from 2 to 15 years, displayed developmental abnormalities including ID (n = 6), motor delay (n = 5), absent/delayed speech (n = 4), regression (n = 2), and/or prenatal growth retardation (n = 1). Additional neurological features included seizures (n = 5), hypotonia (n = 4), ataxia (n = 3), sleeping problems (n = 2), and hearing loss (n = 1). Previous reports have indicated that some individuals with pathogenic DEAF1 variants display a high threshold to pain, however, this feature was not reported for individuals in our cohort at the time of evaluation. Neurobehavioral abnormalities observed in our cohort included autism (n = 5), aggression (n = 2), and self-injury (n = 2), with one individual displaying pica. Previous studies have reported that a majority of individuals harboring DEAF1 mutations experience mood swings and excessive irritability, but these features were not indicated in our patients. Other dysmorphic features frequently observed in our cohort included brain abnormalities (n = 4), mild craniofacial features (n = 3), and various skeletal abnormalities. Several subjects were also noted to have frequent Infections, feeding difficulties, and digestive abnormalities (Table 2) .
Functional characterization of DEAF1 variants
We performed functional assays to assess the effects of the amino acid substitutions or deletion on human DEAF1 protein activity. Previous studies have shown that the WT DEAF1 protein represses its own promoter activity through binding to a site in its promoter region Figure S2 ).
Proteins were tested for DNA binding affinity to the DEAF1 consensus sequences in EMSA using two verified probes, N52-69 (Bottomley et al., 2001; Michelson et al., 1999) and S6con Vulto-van Silfhout et al., 2014) . Compared with WT DEAF1, the variants p.G212S, p.W234R, and p.R246T showed significantly decreased binding to both dsDNA probes. By contrast, the p.K305del variant displayed binding similar to that of WT-DEAF1. The control ADWA variant showed severely diminished binding to both dsDNA probes (Figure 3) . EMSA was also performed using a series of decreasing amounts of WT, p.R226W, or p.K305del proteins to detect changes in relative binding affinity to the N52-69 probe. A dose-dependent decrease in DNA binding was observed for each protein, however no observable differences in relative DNA binding affinity were observed comparing WT DEAF1 and p.K305del or p.R226W proteins (Supp. Figures S3 and   S4 ).
Immunofluorescence staining in transfected cells was used to assess whether the DEAF1 variants had altered subcellular F I G U R E 3 DEAF1 variants have altered DNA binding. Electrophoretic mobility shift assays (EMSA) showed decreased DNA binding affinity of the four novel DEAF1 variants to the 11-space and 6-space double stranded DNA DEAF1 binding sequences (Vulto-van Silfhout et al., 2014) , compared to WT DEAF1. The DEAF1 ADWA variant, which has previously been shown to be defective in binding DNA (Bottomley et al., 2001) , was used as a negative control localizations. WT DEAF1, p.G212S, p.W234R, p.R246T, and pR226W localized exclusively to the nucleus, while the p.K305del variant was predominantly localized to the cytoplasm ( Figure 4A ). Possible protein interactions between WT DEAF1 and the p.K305del variant were examined using an immunofluorescence interaction assay in cells coexpressing WT DEAF1 and p.K305del. Most of the p.K305del protein re-localized to the nucleus in cells co-expressing WT DEAF1, with a fraction of the WT DEAF1 localized to the cytoplasm ( Figure 4B ).
These observations suggest that, in the heterozygous condition, interactions between WT and mutant DEAF1 can alter the localization of both proteins.
DISCUSSION
Trio-based CES is increasingly becoming a first-tier clinical test to identify genetic variants associated with pediatric neurological abnormalities, which are frequently the result of de novo variants in probands (Rauch et al., 2012; Vissers et al., 2010) . To determine whether de novo variants within protein coding regions are pathogenic, it is essential to perform functional assays to assess the effect of the amino acid substitution on properties of the encoded protein. In this study, we identified two previously unreported de novo DEAF1 variants within the SAND and NLS domains, p.G212S and p.K305del, in a cohort of individuals with neurological abnormalities of an unknown etiology through CES. We provide molecular evidence suggesting that these variants and two reported DEAF1 variants (p.W234R (Berger et al., 2017) , p.R246T (Wenger et al., 2017) Jensik et al., 2012). In particular, the DEAF1 SAND domain is required to repress its own promoter activity (Bottomley et al., 2001 ) and stimulate or repress the expression of various target genes, for example, eukaryotic translation initiation factor four gamma three (Eif4g3) and 5-hydroxytryptamine receptor 1A (5-HT1A) (Czesak et al., 2012; Czesak et al., 2006) . The SAND domain also mediates DEAF1 multimerization, which is required for DNA binding (Jensik et al., 2004) and interactions with X-ray repair cross-complementing protein 6 (XRCC6 or Ku70) (Jensik et al., 2012 Homozygosity of the p.R226W variant was previously identified in three individuals with ID, microcephaly, and hypotonia from two consanguineous families. Two of these patients presented with white matter disease and cortical gyri abnormalities, and one experienced fatal complications, but no functional consequences of the p.R226W variant have been reported (Faqeih et al., 2014; Gund et al., 2016) . Homozygosity of the same variant was also identified in our cohort. In silico analysis revealed that the tryptophan substitution may sterically hinder normal protein folding (Faqeih et al., 2014) . In this study, we showed that p.R226W localizes to the nucleus ( Figure 4 ) and observed no significant alterations in DEAF1 transcriptional activity (Figure 2 ).
Although deleterious effects of the p.R226W variant on DEAF1 function have not yet been detected, it is plausible that this amino acid substitution produces pathogenic effects by disrupting transcriptional regulation of specific downstream DEAF1 target genes or modulating DEAF1-protein interactions. Further study will be needed to identify alterations in DEAF1 function/activity due to the p.R226W
substitution.
The monopartite NLS in DEAF1 is necessary for proper subcellular localization and protein-protein interactions (Jensik et al., 2004) . Here, we identified a deletion within the DEAF1 NLS domain, p.K305del, that causes the mutant protein to localize primarily to the cytoplasm (Figure 4) . Although p.K305del does not appear to affect the binding of DEAF1 to DNA in vitro, the observed inability of exogenously expressed p.K305del DEAF1 to repress transcriptional activity at the DEAF1 promoter (Figure 2 ) is likely the consequence of its cytoplasmic localization and limited access to the DEAF1 promoter in the nucleus. The lack of access to DNA in the nucleus may result in similar transcriptional outcomes to those observed with the de novo DEAF1 SAND variants. When we exogenously co-expressed WT DEAF1 and p.K305del in HEK293T cells to mimic the heterozygous condition in Subject 6, nuclear and cytoplasmic localizations were observed for both proteins ( Figure 4B ). These data likely indicate that DEAF1-DEAF1 protein interactions can re-localize p.K305del DEAF1 to the nucleus and partially localize WT protein to the cytoplasm. These observations suggest that individuals heterozygous for p.K305del may have constitutively insufficient quantities of nuclear WT DEAF1, possibly resulting in impaired transcriptional repression activity. The cytoplasmic DEAF1 may also re-localize some as-yet-to-be-determined F I G U R E 4 Subcellular localization of DEAF1 variants and changes in localization of WT DEAF1 and p.K305del in cells co-expressing both proteins. A: Immunofluorescence analysis of WT DEAF1 and DEAF1 variants in transfected HEK293T cells revealed nuclear localization for variants p.G212S, p.R226W, p.W234R, and p.R246T, and cytoplasmic localization for p.K305del. DEAF1 protein is shown in red in the upper panels, nuclei in blue in the middle panels, and merged signals in the bottom set of panels. B: Protein interactions between WT DEAF1 and p.K305del were monitored by immunofluorescence analysis. Co-expression of these two proteins resulted in nuclear and cytoplasmic localization of both proteins (columns 3 and 4). HA epitope-tagged DEAF1 protein is shown in red in the upper panel, FLAG epitope-tagged p.K305del in green in the middle, and nuclei in blue in the bottom cofactor that is needed for proper DEAF1 function in the nucleus. Further functional studies are needed to elucidate the mechanisms underlying possible pathogenic effects of this variant.
In summary, this study identified novel de novo DEAF1 variants in patients with ID, developmental delay, and autism spectrum disorder, expanding the phenotype associated with this neurodevelopmental condition and provides molecular evidence that not only variants in the SAND domain but also in the NLS domain may contribute to DAND. Together, these findings illustrate the importance of elucidating the functional consequences of CES genetic VUS to provide correct variant annotation and facilitate clinical diagnoses.
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